

ForPatients

by Roche

Colorectal Cancer (CRC) Non-Small Cell Lung Cancer (NSCLC) Non Small Cell Lung Carcinoma

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Trial Status
Completed

Trial Runs In
3 Countries

Trial Identifier
NCT05954871 2022-502530-10-00
GO44272

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT05954871 2022-502530-10-00 GO44272
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
